Idorsia announces financial results for 2022 – building momentum
to become a leading mid-sized biopharmaceutical company
Simon Jose, our CCO
takes us through
"The year of launch"
“The rapid progress made by Idorsia in a relatively short time is a huge achievement.”
“2022 was a transformative year for Idorsia – and our achievements have laid the foundations for success in 2023.”
The purpose of Idorsia is to discover, develop and bring more, innovative medicines to patients.
Idorsia’s success depends on its people.
Idorsia's development compounds target a number of different diseases.
| 07 Feb 2023 | |
| 06 Feb 2023 | |
| 31 Jan 2023 |
| Event | When |
|
First Quarter 2023 Financial Results reporting* |
April 25, 2023
|
|
Annual General Meeting of Shareholders |
May 4, 2023 |
|
Half-Year 2023 Financial Results reporting* |
July 25, 2023 |
|
Nine-months 2023 Financial Results reporting* |
October 24, 2023 |
*We will be in a silent period for 10 days ahead of the financial reporting.
